Total Payments
$1,135
2023 Payments
$149.18
Companies
17
Transactions
58
Medicare Patients
1,763
Medicare Billing
$200,128
Payment Breakdown by Category
Food & Beverage$1,027 (90.5%)
Education$107.79 (9.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,027 | 56 | 90.5% |
| Education | $107.79 | 2 | 9.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $559.55 | 30 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $125.01 | 1 | $0 (2023) |
| RedHill Biopharma Inc. | $71.67 | 5 | $0 (2021) |
| Allergan Inc. | $63.24 | 4 | $0 (2019) |
| Gilead Sciences, Inc. | $49.72 | 3 | $0 (2022) |
| UCB, Inc. | $44.84 | 2 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $41.21 | 2 | $0 (2017) |
| Siemens Medical Solutions USA, Inc. | $25.07 | 1 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $24.17 | 1 | $0 (2023) |
| Boston Scientific Corporation | $20.57 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $149.18 | 2 | Janssen Pharmaceuticals, Inc ($125.01) |
| 2022 | $97.34 | 6 | ABBVIE INC. ($44.18) |
| 2021 | $332.59 | 20 | AbbVie Inc. ($243.02) |
| 2020 | $243.55 | 11 | AbbVie Inc. ($176.33) |
| 2019 | $44.99 | 2 | Siemens Medical Solutions USA, Inc. ($25.07) |
| 2018 | $78.66 | 5 | AbbVie, Inc. ($49.95) |
| 2017 | $188.76 | 12 | AbbVie, Inc. ($46.07) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 3 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2017 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/30/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Immunology | ||||||
| 06/21/2017 | AbbVie, Inc. | Creon (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Endocrinology | ||||||
| 04/25/2017 | Valeant Pharmaceuticals North America LLC | XIFAXANIBSD (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/09/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/08/2017 | Takeda Pharmaceuticals America, Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $10.16 | General |
| Category: Lower GI | ||||||
| 02/08/2017 | Takeda Pharmaceuticals America, Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $3.18 | General |
| Category: Lower GI | ||||||
| 01/30/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 354 | 389 | $164,216 | $43,656 |
| 2022 | 10 | 363 | 391 | $201,266 | $42,252 |
| 2021 | 16 | 639 | 717 | $341,668 | $71,574 |
| 2020 | 12 | 407 | 503 | $163,844 | $42,645 |
Total Patients
1,763
Total Services
2,000
Medicare Billing
$200,128
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 34 | 34 | $27,404 | $7,473 | 27.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 42 | 46 | $25,852 | $6,404 | 24.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $21,888 | $5,985 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 58 | $11,716 | $4,188 | 35.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 41 | 41 | $12,259 | $3,648 | 29.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 19 | 19 | $16,758 | $3,618 | 21.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 39 | 39 | $17,511 | $3,508 | 20.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 29 | $11,020 | $2,846 | 25.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 41 | $8,282 | $2,621 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 17 | $5,066 | $1,787 | 35.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $6,460 | $1,578 | 24.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 58 | 60 | $70,704 | $11,454 | 16.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 50 | 50 | $28,872 | $8,419 | 29.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $17,050 | $4,435 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 64 | $11,920 | $3,640 | 30.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 41 | 42 | $31,658 | $3,582 | 11.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 41 | 41 | $11,349 | $2,934 | 25.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 21 | $11,109 | $2,582 | 23.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 35 | $6,615 | $1,791 | 27.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 19 | $6,783 | $1,714 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 19 | $5,206 | $1,702 | 32.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 76 | 76 | $40,204 | $10,999 | 27.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 91 | 91 | $38,402 | $9,902 | 25.8% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 50 | 52 | $62,296 | $9,528 | 15.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 71 | $19,454 | $5,856 | 30.1% |
About Dr. Michael Schwartz, D.O
Dr. Michael Schwartz, D.O is a Gastroenterology healthcare provider based in Midlothian, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700847514.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Schwartz, D.O has received a total of $1,135 in payments from pharmaceutical and medical device companies, with $149.18 received in 2023. These payments were reported across 58 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,027).
As a Medicare-enrolled provider, Schwartz has provided services to 1,763 Medicare beneficiaries, totaling 2,000 services with total Medicare billing of $200,128. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Midlothian, TX
- Active Since 03/31/2006
- Last Updated 04/16/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1700847514
Products in Payments
- HUMIRA (Biological) $273.69
- MAVYRET (Drug) $132.09
- XARELTO (Drug) $125.01
- Movantik (Drug) $71.67
- Humira (Biological) $45.92
- Cimzia (Drug) $44.84
- XIFAXAN (Drug) $36.11
- Creon (Drug) $32.75
- ZENPEP (Drug) $30.36
- LINZESS (Drug) $29.76
- RINVOQ (Biological) $28.67
- CorPath GRX (Device) $25.07
- DUPIXENT (Biological) $24.17
- XIFAXANIBSD (Drug) $23.59
- SpyGlass (Device) $20.57
- MOTEGRITY (Drug) $17.85
- Trulance (Drug) $17.71
- VIBERZI (Drug) $16.41
- ELEVIEW (Device) $16.23
- CREON (Drug) $15.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.